...Satenik Harutyunova; Nicola Benjamin; Christina Eichstaedt; Alberto M. Marra; Panagiota Xanthouli; Christian Nagel; Ekkehard Grünig; Benjamin Egenlauf Background: Current guidelines recommend treatment with parenteral prostacyclin analogs in patients with severe pulmonary arterial hypertension (PAH...

...Argyro Vraka; Patrick Yerly; John-David Aubert Background: Risk assessment is the cornerstone of pulmonary arterial hypertension (PAH) management. Risk stratification scores predict prognosis and help individualize treatment. Objectives: The aims of the study include the following: (1) to compare...

...) is a prognostic parameter in pulmonary arterial hypertension (PAH) reflecting the elasticity of the pulmonary vessels. Objectives: The objective of this post hoc analysis of a prospective randomized controlled trial (RCT) was to assess the effect of exercise training on PAC and stroke volume (SV) in patients...

... with pulmonary arterial hypertension (PAH). Objectives: The aim of this study was to investigate the prognostic value of pulmonary hemodynamics during exercise and changes during treatment in patients with PAH. Methods: Consecutive incident patients ( n = 49) with PAH undergoing right heart catheterization...

... Blankenberg; Ekkehard Grünig Background: Right ventricular (RV) dysfunction is a major prognostic predictor in pulmonary arterial hypertension (PAH). Objectives: The objective of this study was to assess the prognostic impact of a newly developed index merging haemodynamic parameters into 1 variable. Methods...

... of the immune system is regarded to play an important role in the etiopathobiology of pulmonary arterial hypertension (PAH) and inoperable chronic thromboembolic pulmonary hypertension (CTEPH). To the best of our knowledge, neopterin (NP) has never been investigated in patients with PAH and CTEPH. Objectives...

.... Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension Combination therapy Risk stratification Therapeutic goals The main symptom of precapillary pulmonary hypertension (PH) is progressive dyspnoea on exertion associated with reduced daily activity and impaired quality...

...Benedicte De Muynck; Mathias Leys; Joke Cuypers; Dirk Vanderschueren; Marion Delcroix; Catharina Belge We report the case of a 50-year-old woman with anorexigen-induced pulmonary arterial hypertension treated with epoprostenol, who presented with Trousseau’s sign, leading to the diagnosis of severe...

...Christian Nagel; Ralf Ewert; Benjamin Egenlauf; Hans B. Lehmkuhl; Stephan Rosenkranz; Nicola Benjamin; Vedat Schwenger; Felix J.F. Herth; Ekkehard Grünig Background: Despite optimized medical therapy, severe idiopathic pulmonary arterial hypertension (IPAH) is a devastating disease with a poor...

... or tadalafil and the endothelin receptor antagonists (ERA) bosentan, ambrisentan, or macitentan may cause mutual pharmacokinetic interactions in patients with pulmonary arterial hypertension (PAH). Objective: The objective of this study was to analyze plasma drug concentrations in PAH patients receiving...

...: Subcutaneous treprostinil has dose-dependent beneficial effects in patients with severe pulmonary arterial hypertension, but adverse effects like infusion site pain can lead to treatment discontinuation. Objectives: The objective of this study was to evaluate safety, tolerability and clinical effects...

.... Pulmonary hypertension Pulmonary arterial hypertension Chronic thromboembolic pulmonary hypertension Health-related quality of life Anxiety and depression Pulmonary hypertension (PH) represents a group of rare disorders with a progressive course and a dismal prognosis if untreated [ 1...

...Laurence Gabriel; Xavier Delavenne; Pierrick Bedouch; Chahéra Khouatra; Hélène Bouvaist; Jean-François Cordier; Jean-François Mornex; Christophe Pison; Vincent Cottin; Laurent Bertoletti Background: Patients treated for pulmonary arterial hypertension (PAH) frequently receive vitamin K antagonists...

... Pulmonary arterial hypertension Precapillary pulmonary hypertension (PH) is defined by a mean pulmonary artery pressure of ≥25 mm Hg, along with a pulmonary artery wedge pressure of ≤15 mm Hg [ 1 ]. PH leads to fatigue and reduced exercise capacity and may be associated with cognitive deficits...

... pneumonia Usual interstitial pneumonia-type pulmonary fibrosis Infections Pulmonary embolism Diffuse alveolar hemorrhage Pulmonary arterial hypertension Bronchiolitis Apical fibrobullous disease Lung involvement in connective tissue disorders (CTDs) is common and constitutes a major...

...Rudolf Speich; Silvia Ulrich; Guido Domenighetti; Lars C. Huber; Manuel Fischler; Ursula Treder; Alexander Breitenstein Background: Antiproliferative strategies have emerged as a potential therapeutic option for pulmonary arterial hypertension (PAH). Objective: To evaluate the long-term efficacy...

.... Exercise training Pulmonary arterial hypertension Pulmonary hypertension Rehabilitation Right heart failure Pulmonary hypertension (PH) is a clinical condition characterized by progressive vascular remodeling with increased pulmonary vascular resistance and right ventricular overload that may...

..., transplantation, endarterectomy or loss to follow-up) registered. The data were stratified according to the time of diagnosis into prevalent before 2000 and incident during 2000-2004, 2005-2008 and 2009-2012. Results: From 996 (53% female) PH patients, 549 had pulmonary arterial hypertension (PAH), 36 PH due...

...Manuel Jonas Richter; Henning Tiede; Rory E. Morty; Robert Voswinckel; Werner Seeger; Richard Schulz; Hossein Ardeschir Ghofrani; Frank Reichenberger Background: Patients with pulmonary arterial hypertension (PAH) present with an altered inspiratory capacity (IC) reflecting dynamic hyperinflation...

... from 18,747 presumably healthy participants of the SHS performed in 2007. Data retrieval for this survey was by telephone call [ 8 ]. Chronic thromboembolic pulmonary hypertension Pulmonary hypertension Pulmonary arterial hypertension Tobacco smoke Smoking Risk factor Precapillary...